CEO Kevin Sayer explains how, following the launch of the next-generation Dexcom G7, the company is looking toward the future.
Dexcom (Nasdaq:DXCM) ended 2022 strong, receiving FDA clearance for its next-generation G7 continuous glucose monitor (CGM). With a U.S. launch imminent, the company could keep its efforts centered on the diabetes space.
Instead, the company plans to broaden its focus even wider.
“We’ve revised our mission statement,” Sayer told Drug Delivery Business News. “In the past, we always talked about enabling people to take control of diabetes. We’ve changed diabetes to health. We’re enabling people to take control of their health because metabolic health and glucose values and the information we can provide are very much synonymous.”
Get the full story at our sister site, Drug Delivery Business News.